Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
What is the ticker symbol for Compass Therapeutics Inc? What does CMPX stand for in stocks?
CMPX is the stock ticker symbol of Compass Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Compass Therapeutics Inc (CMPX)?
As of Fri Jul 26 2024, market cap of Compass Therapeutics Inc is 148.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of CMPX stock?
You can check CMPX's fair value in chart for subscribers.
Is Compass Therapeutics Inc a good stock to buy?
The fair value guage provides a quick view whether CMPX is over valued or under valued. Whether Compass Therapeutics Inc is cheap or expensive depends on the assumptions which impact Compass Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMPX.